Search
umeclidinium (Incruse Ellipta)
FDA-approval recommended for combination with vilanterol
Indications:
- COPD
Dosage:
- 62 ug QD via inhalation (MDI)
Adverse effects:
- nasopharyngitis
- upper respiratory tract infection
- cough
- arthralgia
Interactions
drug adverse effects of parasympatholytics
General
inhaled anticholinergic agent
Database Correlations
PUBCHEM correlations
References
- Physician's First Watch, September 12, 2013
David G. Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
- Medscape. April 30, 2014
FDA OKs Umeclidinium (Incruse Ellipta) for COPD.
http://www.medscape.com/viewarticle/824419
Component-of
umeclidinium/vilanterol (Anoro Ellipta)